Überprüfung…
Automatisch übersetzt. Dosierung und Warnhinweise: bitte im englischen Original prüfen. Auf Englisch lesen
Homepage / Eingetragen in Nigeria / Flurbiprofen Sodium Ophthalmic Solution USP 0.03%

Flurbiprofen Sodium Ophthalmic Solution USP 0.03%

NAFDAC Reg.-Nr. B4-5397 Medikament

Registriert bei NAFDAC. Registrierung aktivAs of 30 October 2026 · synced automatically from official sources.
Produkt-
Flurbiprofen Sodium Ophthalmic Solution USP 0.03%
NAFDAC-Nummer
B4-5397
Wirkstoff
Flurbiprofen sodium
Stärke
0.03%
Form
Solution/Drops
Hersteller
Not listed
Applicant (holder)
Lin-Kabs Pharmaceutical Limited
Approved
28 Sep 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
27 Sep 2026
WER WARNT
None found
Community reports
None
Times checked
0

What we found

  • Flurbiprofen Sodium Ophthalmic Solution USP 0.03% is on the NAFDAC register with an active registration (B4-5397). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Flurbiprofen Sodium Ophthalmic Solution USP 0.03%

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Serious warning: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. …
Who it is for

Flurbiprofen tablets are indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. Flurbiprofen tablets are a nonsteroidal anti-inflammatory drug indicated for Relief of the signs and symptoms of rheumatoid arthritis ( 1 ) Relief of the signs and symptoms of osteoarthritis ( 1 )

How to take it and how often
  • Carefully consider the potential benefits and risks of flurbiprofen tablets and other treatment options before deciding to use flurbiprofen tablets
  • Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [ see Warnings and Precautions ]
  • After observing the response to initial therapy with flurbiprofen tablets, the dose and frequency should be adjusted to suit an individual patient's needs
  • For relief of the signs and symptoms of rheumatoid arthritis or osteoarthritis, the dosage is 200 to 300 mg per day, divided for administration two, three, or four times a day
  • The largest recommended single dose in a multiple-dose daily regimen is 100 mg
  • Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals The recommended starting dose of flurbiprofen tablets is 200 to 300 mg per day, divided for administration two, three, or four times a day
  • The largest recommended single dose in a multiple-dose daily regimen is 100 mg
Strengths it comes in

Flurbiprofen Tablets, USP: 100 mg round, convex, blue, film-coated tablets debossed "NH" and "100" Tablets: 100 mg ( 3 )

Children
  • Safety and effectiveness
  • In pediatric patients have not been established
Older adults

Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [ see Warnings and Precautions (5.1 , 5.2 , 5.3 , 5.6 , 5.14) ].

While you are taking it
  • Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed
  • Inform patients, families, or their caregivers of the following information before initiating therapy with flurbiprofen and periodically during the course of ongoing therapy
  • Cardiovascular Thrombotic Events Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately [ see Warnings and Precautions ]. …
Talk to a doctor first if

Flurbiprofen tablets are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to flurbiprofen or any components of the drug product [ see Warnings and Precautions (5.7 , 5.9) ] History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. …

Medicines it may not mix with

See Table 1 for clinically significant drug interactions with flurbiprofen. Table 1: Clinically Significant Drug Interactions with Flurbiprofen Drugs That Interfere with Hemostasis Clinical Impact: Flurbiprofen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of flurbiprofen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. …

Warnings

Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop ( 5.3 ) Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure ( 5.4 , 7 ) Heart Failure and Edema : Avoid use of flurbiprofen in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (5.5) Renal Toxicity : Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. …

Possible side effects

The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions (5.1) ] GI Bleeding, Ulceration and Perforation [ see Warnings and Precautions (5.2) ] Hepatotoxicity [ see Warnings and Precautions (5.3) ] Hypertension [ see Warnings and Precautions (5.4) ] Heart Failure and Edema [ see Warnings and Precautions (5.5) ] Renal Toxicity and Hyperkalemia [ see Warnings and Precautions (5.6) ] Anaphylactic Reactions [ see Warnings and Precautions (5.7) ] Serious Skin Reactions [ see Warnings and Precautions (5.9) ] Hematologic Toxicity [ see Warnings and Precautions (5.12) ] Most common adverse react …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary Use of NSAIDs, including flurbiprofen tablets, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. …

If you take too much

Symptoms following acute NSAID overdosages have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression and coma have occurred, but were rare [ see Warnings and Precautions (5.1 , 5.2 , 5.4 , 5.6) ]. Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. …

How to store it

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-02-03.

Label for flurbiprofen sodium, the active ingredient registered with NAFDAC.

Check your pack of Flurbiprofen Sodium Ophthalmic Solution USP 0.03%

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · NAFDAC · WHO alerts

About Flurbiprofen Sodium Ophthalmic Solution USP 0.03%

What is in Flurbiprofen Sodium Ophthalmic Solution USP 0.03%?

Flurbiprofen Sodium Ophthalmic Solution USP 0.03% contains Flurbiprofen sodium (0.03%), as solution/drops, according to its NAFDAC registration record.

Is Flurbiprofen Sodium Ophthalmic Solution USP 0.03% registered with NAFDAC?

Yes. Flurbiprofen Sodium Ophthalmic Solution USP 0.03% is listed on the NAFDAC register under registration number B4-5397, and its registration is active as of 30 October 2026.

Has Flurbiprofen Sodium Ophthalmic Solution USP 0.03% been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Flurbiprofen Sodium Ophthalmic Solution USP 0.03% in our automatically synced alert list.

How can I check that my pack of Flurbiprofen Sodium Ophthalmic Solution USP 0.03% is genuine?

Run a free authenticity scan with the NAFDAC number B4-5397, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Flurbiprofen Sodium Ophthalmic Solution USP 0.03%?

Follow your prescription or the leaflet in your pack. The official label says: Carefully consider the potential benefits and risks of flurbiprofen tablets and other treatment options before deciding to use flurbiprofen tablets. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [ see Warnings and Precautions (5) ]. After observing the response to initial therapy with flurbiprofen tablets, the dose …

What is Flurbiprofen Sodium Ophthalmic Solution USP 0.03% used for?

Flurbiprofen tablets are indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. Flurbiprofen tablets are a nonsteroidal anti-inflammatory drug indicated for Relief of the signs and symptoms of rheumatoid arthritis ( 1 ) Relief of the signs and symptoms of osteoarthritis ( 1 ) (Summarised from the official U.S. FDA label for flurbiprofen sodium. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Flurbiprofen Sodium Ophthalmic Solution USP 0.03%? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.